No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	MCLA-158 Sensitive: B - Late Trials MCLA-158 Sensitive : B	MCLA-158 Sensitive: B - Late Trials MCLA-158 Sensitive : B
NRAS wild-type	Colorectal Cancer	NRAS wild-type	Colorectal Cancer	CPGJ-602 Sensitive: C2 – Inclusion Criteria CPGJ-602 Sensitive : C2	CPGJ-602 Sensitive: C2 – Inclusion Criteria CPGJ-602 Sensitive : C2
BRAF wild-type	Colorectal Cancer	BRAF wild-type	Colorectal Cancer	CPGJ-602 Sensitive: C2 – Inclusion Criteria CPGJ-602 Sensitive : C2	CPGJ-602 Sensitive: C2 – Inclusion Criteria CPGJ-602 Sensitive : C2
KRAS wild-type	Colorectal Cancer	KRAS wild-type	Colorectal Cancer	CPGJ-602 Sensitive: C2 – Inclusion Criteria CPGJ-602 Sensitive : C2	CPGJ-602 Sensitive: C2 – Inclusion Criteria CPGJ-602 Sensitive : C2
BRAF wild-type	Colorectal Cancer	BRAF wild-type	Colorectal Cancer	SCT200 Sensitive: C2 – Inclusion Criteria SCT200 Sensitive : C2	SCT200 Sensitive: C2 – Inclusion Criteria SCT200 Sensitive : C2
KRAS wild-type	Colorectal Cancer	KRAS wild-type	Colorectal Cancer	SCT200 Sensitive: C2 – Inclusion Criteria SCT200 Sensitive : C2	SCT200 Sensitive: C2 – Inclusion Criteria SCT200 Sensitive : C2
TP53 mutation	Esophageal Squamous Cell Carcinoma	TP53 mutation	Esophageal Squamous Cell Carcinoma	SCT200 Sensitive: C3 – Early Trials SCT200 Sensitive : C3	SCT200 Sensitive: C3 – Early Trials SCT200 Sensitive : C3
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	rezivertinib Sensitive: C3 – Early Trials rezivertinib Sensitive : C3	rezivertinib Sensitive: C3 – Early Trials rezivertinib Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	rezivertinib Sensitive: C3 – Early Trials rezivertinib Sensitive : C3	rezivertinib Sensitive: C3 – Early Trials rezivertinib Sensitive : C3
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	CKD-702 Sensitive: C3 – Early Trials CKD-702 Sensitive : C3	CKD-702 Sensitive: C3 – Early Trials CKD-702 Sensitive : C3
NRAS wild-type	Colorectal Cancer	NRAS wild-type	Colorectal Cancer	SCT200 Sensitive: C3 – Early Trials SCT200 Sensitive : C3	SCT200 Sensitive: C3 – Early Trials SCT200 Sensitive : C3
MET overexpression	Lung Adenocarcinoma	MET overexpression	Lung Adenocarcinoma	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D
MET exon 14 deletion	Non Small Cell Lung Cancer	MET exon 14 deletion	Non Small Cell Lung Cancer	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	MCLA-158 Sensitive: D – Preclinical MCLA-158 Sensitive : D	MCLA-158 Sensitive: D – Preclinical MCLA-158 Sensitive : D

EGFR antagonist

EGFR antagonist

Associations(17)

Associations
(17)